Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance

Luo, Liu; Diamandis, Eleftherios P.; Look, Maxime P.; Soosaipillai, Antoninus; Foekens, John A.

doi:10.1038/sj.bjc.6600323

Cited by 54 publications

(32 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More precisely, KLK10 protein tissue accumulation was revealed to be an independent biomarker, predicting patients' resistance to tamoxifen treatment. Higher KLK10 tissue levels have been correlated with stronger resistance to tamoxifen, indicating the need for a redesign of the initial therapeutic scheme (Luo et al, 2002). Moreover, similar conclusions, regarding tamoxifen resistance, can also be drawn by the assessment of higher cytosolic PSA/KLK3 concentration in primary BC (Foekens et al, 1999).…”

Section: Klks As Cancer Monitoring Biomarkerssupporting

confidence: 55%

“…Stronger KLK4 ovarian cancer tissue staining has been observed in patients more resistant to paclitaxel administration, revealing the significance of this peptidase in stratifying patients for paclitaxel-based chemotherapy (Xi et al, 2004). Moreover, presurgically higher KLK10 serum concentrations have been found to be significantly correlated with ovarian cancer patients' poor response to chemotherapy (Luo et al, 2002). Contrary to KLK10, higher KLK11 and KLK13 tissue protein levels are more frequently associated with women showing an enhanced clinical response to chemotherapy, suggesting that this treatment option is suitable and effective for these patients, whereas the combination of the assessment of KLK6 and KLK8 tissue levels with those of KLK13 yields an enhanced monitoring potential (Borgono et al, 2003;Zheng et al, 2007).…”

Section: Klks As Cancer Monitoring Biomarkersmentioning

confidence: 85%

See 1 more Smart Citation

Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies

Avgeris

Mavridis

Scorilas

2010

Biological Chemistry

View full text Add to dashboard Cite

Tissue kallikrein (KLK1) and the kallikrein-related peptidase (KLK2-15) genes encode for a subgroup of 15 homologous secreted serine proteases possessing numerous physiological roles, such as the regulation of blood pressure, hormone processing and tissue remodeling. The expression of KLKs is detected in a broad spectrum of human tissues where it has been found to be regulated mainly by steroids hormones. The aberrant expression of KLKs, presented in many human malignancies, highlights the significance of this gene family for early diagnosis, prognosis and monitoring of cancer patients, as it is strongly emphasized by the routine use of PSA (KLK3) for prostate cancer management. Here, we review the presently known data regarding the role of KLKs as cancer biomarkers, giving emphasis on novel information about the subject.

show abstract

Section: Klks As Cancer Monitoring Biomarkerssupporting

confidence: 55%

Section: Klks As Cancer Monitoring Biomarkersmentioning

confidence: 85%

Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies

Avgeris

Mavridis

Scorilas

2010

Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…For patients with advanced breast cancer, a very limited number of studies (all from our laboratory) addressing the relation of serine proteases with the efficacy of systemic treatment are available. In this respect, we showed that high tumour levels of uPA (Foekens et al, 1995), kallikrein 3 , or kallikrein 10 (Luo et al, 2002) were significantly associated with a poor rate of response to tamoxifen therapy. In the present study, we investigated the predictive value of PMN-E for the efficacy of tamoxifen and chemotherapy in patients with advanced breast cancer.…”

Section: Discussionmentioning

confidence: 76%

“…For breast cancer patients who received systemic therapy for advanced disease, only three studies are available relating the levels of serine proteases, that is, uPA (Foekens et al, 1995), human kallikrein 3 (PSA) , or human kallikrein 10 (Luo et al, 2002) to a poor efficacy of first-line tamoxifen treatment. With respect to the predictive value of serine proteases for response to chemotherapy in advanced breast cancer, no published studies are yet available.…”

mentioning

confidence: 99%

Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease

et al. 2003

Self Cite

View full text Add to dashboard Cite

Besides a variety of other proteases, polymorphonuclear leukocyte elastase (PMN-E) is also suggested to play a role in the processes of tumour cell invasion and metastasis. Yet, there is only limited data available on the relation between the tumour level of PMN-E and prognosis in patients with primary breast cancer, and no published information exists on its relation with the efficacy of response to systemic therapy in patients with advanced breast cancer. In the present study, we have measured with enzyme-linked immunosorbent assay the levels of total PMN-E in cytosolic extracts of 463 primary breast tumours, and have correlated their levels with the rate and duration of response on first-line tamoxifen therapy (387 patients) or chemotherapy (76 patients) in patients with locally advanced and/or distant metastatic breast cancer. Furthermore, the probabilities of progression-free survival and postrelapse survival were studied in relation to the tumour levels of PMN-E. Our results show that in logistic regression analysis for response to tamoxifen treatment in patients with advanced disease, high PMN-E tumour levels were associated with a poor rate of response compared with those with low PMN-E levels (odds ratio: OR, 0.40; 95% CI, 0.22 -0.73; P ¼ 0.003). After correction for the contribution of the traditional predictive factors in multivariate analysis, the tumour PMN-E status was an independent predictor of response (P ¼ 0.01). Furthermore, a high tumour PMN-E level was related with a poor progression-free survival (Po0.001) and postrelapse survival (P ¼ 0.002) in a time-dependent analysis. In contrast, the tumour level of PMN-E was not significantly related with the efficacy of response to first-line chemotherapy in patients with advanced breast cancer. Our present results suggest that PMN-E is an independent predictive marker for the efficacy of tamoxifen treatment in patients with advanced breast cancer.

show abstract

“…Furthermore, a number of preliminary analyses suggest that certain kallikreins including KLK3 (Yu et al, 1995;Yu et al, 1998;Foekens et al, 1999), KLK5 (Yousef et al, 2002b(Yousef et al, , 2003cDiamandis et al, 2003), KLK7 (Talieri et al, 2004), KLK9 (Yousef et al, 2003a), KLK10 (Luo et al, 2002), KLK13 (Chang et al, 2002), KLK14 , KLK15 (Yousef et al, 2002c) may possess clinical utility as diagnostic, prognostic or predictive breast cancer biomarkers. For recent reviews on the human kallikrein family please see references Clements et al, 2004).…”

mentioning

confidence: 99%

Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status

Fritzsche

Gansukh

et al. 2006

Br J Cancer

Self Cite

View full text Add to dashboard Cite

Human kallikrein 14 (KLK14) is a steroid hormone-regulated member of the tissue kallikrein family of serine proteases, for which a prognostic and diagnostic value in breast cancer has been suggested. To further characterise the value of KLK14 as a breast tumour marker, we have carefully analysed KLK14 expression in normal breast tissue and breast cancer both on the RNA level by real-time RT-PCR (n ¼ 39), and on the protein level (n ¼ 127) using a KLK14-specific antibody for immunohistochemistry. We correlated KLK14 protein expression data with available clinico-pathological parameters (mean follow-up time was 55 months) including patient prognosis. KLK14 RNA expression as quantified by real-time RT-PCR was significantly more abundant in breast tumours compared to normal breast tissue (P ¼ 0.027), an issue that had not been clarified recently. Concordantly with the RNA data, cytoplasmic KLK14 protein expression was significantly higher in invasive breast carcinomas compared to normal breast tissues (P ¼ 0.003). Furthermore, KLK14 protein expression was associated with higher tumour grade (P ¼ 0.041) and positive nodal status (P ¼ 0.045) but was not significantly associated with shortened disease-free or overall patient survival time in univariate analyses. We conclude that KLK14 is clearly overexpressed in breast cancer in comparison to normal breast tissues and is positively associated with conventional parameters of tumour aggressiveness, but due to a missing association with survival times, the use of KLK14 immunohistochemistry as a prognostic marker in breast cancer is questionable.

show abstract

Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance

Cited by 54 publications

References 37 publications

Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies

Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies

Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease

Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status

Contact Info

Product

Resources

About